Tuesday, 21 October 2025
  
Login

Australia's most trusted
source of pharma news

Tuesday, 21 October 2025
News

New data lifts three PBAC hopefuls

Posted 21 October 2025 AM

Pfizer has new ammunition for the PBAC after the release of a trio of Phase 3 trials over the weekend, although all the drugs are sponsored by partners in Australia.

Pfizer and Astellas announced the final overall survival results from the Phase 3 EMBARK study, which evaluated Xtandi as a monotherapy and in combination with androgen deprivation therapy (ADT) leuprorelin (called leuprolide in the study) to treat metastatic hormone-sensitive prostate cancer, which saw eight-year overall survival rise to 78.9 per cent for patients taking the combination compared to 69.5 per cent for leuprorelin alone.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (13)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (1)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.